News – Page 964 – Endpoints News

AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases

7 years ago

Vivek Ramaswamy launches yet another Vant, this time in Asia with a TCR-focused Medigene partnership

7 years ago

Eyeing a fast pitch for quick OK in race with bluebird, J&J/Legend team enjoys a regulatory embrace for their rival ...

7 years ago

NIH unveils a vaccine candidate for universal flu jab as first-in-human studies get underway

7 years ago

NGM bags $107M from an IPO designed to back their play in the big NASH R&D race

7 years ago

To be cost-effective, Biogen should slash Spinraza price, and Novartis cannot justify a $4M-$5M price tag for ...

7 years ago

Biotech billionaire faces accusations of fraud for $1.3B 'catch-and-kill' cancer drug deal

7 years ago

Vas Narasimhan has high hopes for Novartis' China drive as a blockbuster drug gets a nod

7 years ago

Cigna/Express Scripts offer diabetics $25/month insulin; Pfizer's Vizimpro scores EU nod

7 years ago

AbbVie shareholder joins the growing ranks of critics, calling for an independent chairman

7 years ago

Watch out Eli Lilly, AbbVie and Biogen: 7 new blockbusters are on their way to shake things up

7 years ago

After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo ...

7 years ago

As Spark shareholders balk, FTC holdup helps delay Roche's $4.3B buyout

7 years ago

Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies

7 years ago

European players set up one-stop bacterial strain shop for microbiome-focused drug developers

7 years ago

Romesh Subramanian births a new biotech with $50M and a plan to steer toward the clinic with drugs for rare muscle ...

7 years ago

Belgian biotech founded by University of Torino team nabs $23.5 million in Series A round

7 years ago

Rubius cites some preclinical progress; Xencor scores deal with Astellas; Eidos to restate quarterly filings

7 years ago

Another day, another $100M-plus biotech megaround as radiopharmaceuticals’ popularity grows

7 years ago

Laser-activated eye cancer drug developer Aura Biosciences scores $40M in Medicxi-led round

7 years ago

Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?

7 years ago

Sangamo bounces back with upbeat snapshot on hem A allied with Pfizer and a plan to beef up AAV manufacturing

7 years ago

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

7 years ago

Evoke's sole treatment fails to evoke the FDA's confidence, as agency rejects Gimoti after flagging concerns last ...

7 years ago

First page Previous page 961 962 963964965 966 967 Next page Last page